Company intelligence / Profile preview

LAGeT

Ownership: Private
Development stage: Other

Overview

LAGeT is a biotechnology company focused on developing a novel platform for ligand-activated gene therapy. The company's core technology enables the precise control of therapeutic gene expression through the administration of specific, small-molecule ligands. This approach aims to overcome the limitations of traditional gene therapies by providing a mechanism to modulate or terminate treatment as needed. LAGeT is currently exploring applications in inflammatory and autoimmune diseases, where regulated expression of anti-inflammatory proteins could offer significant therapeutic advantages.

Therapeutic areas: Immunology
Modalities: Gene therapy
Industry: Biotech

Beyond the preview

Go deeper on LAGeT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAGeT.

Explore the full profile